Enlarge / Demonstrators take part in an abortion-rights rally exterior the Supreme Court docket because the justices of the court docket hear oral arguments within the case of the US Meals and Drug Administration v. Alliance for Hippocratic Medication on March 26, 2024 in Washington, DC. (credit score: Getty | Anna Moneymaker)
The US Supreme Court docket on Tuesday heard arguments in a case in search of to restrict entry to the abortion and miscarriage drug mifepristone, with a majority of justices expressing skepticism that the anti-abortion teams that introduced the case have the authorized standing to take action.
The case threatens to dramatically alter entry to a drug that has been safely used for many years and, in keeping with the Guttmacher Institute, was utilized in 63 % of abortions documented within the well being care system in 2023. However, it additionally has sweeping implications for the Meals and Drug Administration’s authority over medicine, marking the primary time that courts have second-guessed the company’s knowledgeable scientific evaluation and moved to limit entry to an FDA-approved drug.
As such, the case has rattled well being consultants, reproductive well being care advocates, the FDA, and the pharmaceutical business alike. However, based mostly on the road of questioning in in the present day’s oral arguments, they’ve motive to breathe a sigh of aid.
Learn 11 remaining paragraphs | Feedback
